

iShares HlthcInnvtnUCITSETF £

Fund Information

Sector

Equity - Pharma Health & Biotech

Manager's Name

N/A

Date Manager Appointed

N/A

Launch Date

Sep 2016

Fund Size(£m)

£2511.14

Yield* (See page2)

0.00 %

XD Dates

N/A

Last Distribution

N/A (XD Date)

N/A (Pay Date)

N/A(Distribution)

OCF

0.40 %

Morningstar Analyst Rating

N/A


FE Crown Rating

Fund Aim

The Share Class is a share class of a Fund which aims to achieve a return on your investment, through a combination of capital growth and income on the Fund's assets, which reflects the return of the iSTOXX® FactSet Breakthrough Healthcare Index, the Fund's benchmark index (Index). The Share Class, via the Fund, invests in equity securities (e.g. shares) that, so far as possible and practicable, make up the Index. The Index reflects the performance of a subset of equity securities within the STOXX Global Total Market Index (TMI) ("Parent Index") which derive significant revenues from healthcare innovation. Companies included in the Index must generate at least 50% of their annual revenues from one or multiple predefined sectors relevant to the healthcare innovation theme, which fall under categories such as generic drugs, immunotherapy (e.g. stem cell treatment) and healthcare IT. The Index methodology looks down through six layers of subsectors in order to provide a focused exposure to the specific theme. If a company's aggregate revenue received from the predefined sectors drops below 45% it will be removed from the Index at the next rebalance. The Index may include small, mid and/or large capitalisation constituents of the Parent Index from both developed and emerging market countries globally. The Parent Index is free float market capitalisation weighted, however, each constituent of the Index is equally weighted at each Index rebalance. In order to gain exposure to certain securities in emerging markets that make up its Index, the Fund may invest in American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). ADRs and GDRs are investments issued by financial institutions which give exposure to underlying equity securities.

Sector: Equity - Pharma Health & Biotech

Performance




| Discrete Performance - 12 months to 31/12/20 | | | | | |
|--|-------|-------|-------|-------|-------|
| | 2020 | 2019 | 2018 | 2017 | 2016 |
| Fund | 47.43 | 8.34 | 3.79 | 23.34 | - |
| Stock Sector Average | 18.33 | 23.41 | -3.12 | 13.10 | -9.26 |


| Cumulative Performance to 31/07/21 | | | | | |
|------------------------------------|-------|-------|-------|-------|-------|
| | 1 Yr | 2 Yrs | 3 Yrs | 4 Yrs | 5 Yrs |
| Fund | 20.08 | 43.05 | 46.95 | 83.58 | - |
| Stock Sector Average | 18.76 | 40.21 | 42.22 | 55.38 | 65.14 |

| Performance Analysis - Annualised 3 years | | | | | |
|---|-------------|--|--|--|--|
| | Growth Rate | | | | |
| Fund | | | | | |
| Stock Sector Average | | | | | |

Fund Composition



| | (%) |
|-----------------------|-------|
| US Equities | 66.77 |
| Japanese Equities | 5.01 |
| South Korean Equities | 4.68 |
| Chinese Equities | 4.24 |
| German Equities | 3.47 |
| Swiss Equities | 2.95 |
| Belgian Equities | 2.30 |
| Indian Equities | 2.25 |
| Swedish Equities | 2.09 |
| Others | 6.24 |



| | (%) |
|-------------|-------|
| USA | 66.77 |
| Japan | 5.01 |
| Korea | 4.68 |
| China | 4.24 |
| Germany | 3.47 |
| Switzerland | 2.95 |
| Belgium | 2.30 |
| India | 2.25 |
| Sweden | 2.09 |
| Others | 6.24 |

Largest Holdings

| Holdings | (%) |
|---------------------------|------|
| NOVOCURE LTD | 2.76 |
| NUANCE COMMUNICATIONS INC | 2.03 |
| NATERA INC | 1.86 |
| GUARDANT HEALTH INC | 1.83 |
| HALOZYME THERAPEUTICS INC | 1.82 |

| Holdings | (%) |
|------------------------|------|
| BEIGENE LTD | 1.82 |
| CRISPR THERAPEUTICS AG | 1.72 |
| FATE THERAPEUTICS | 1.65 |
| PENUMBRA INC | 1.61 |
| BIO-TECHNE CORP | 1.55 |

* Data supplied by fund managers regarding fixed interests funds may not specify yield type. As the provision of redemption yield is an FCA regulatory requirement Novia assumes these are used.

Important Information

Performance details and yields are as at 31/07/2021. Performance figures are inclusive of net reinvested income. Source: FE. This document is designed only for professional investors and experienced advisers. The value of investments and the income gained may fluctuate. Investors may not get back the full amount invested. Past performance is not a guide to the future.